Holen Sie sich die Stockscreener-App
11.10
2.03%
-0.25
Schlusskurs vom Vortag:
$11.35
Offen:
$11.51
24-Stunden-Volumen:
61,037
Relative Volume:
0.53
Marktkapitalisierung:
$190.48M
Einnahmen:
$6.67M
Nettoeinkommen (Verlust:
$-47.55M
KGV:
-7.40
EPS:
-1.5
Netto-Cashflow:
$-17.44M
1W Leistung:
-4.14%
1M Leistung:
-10.97%
6M Leistung:
+2,075%
1J Leistung:
+2,075%
1-Tages-Spanne:
$10.97
$12.27
1-Wochen-Bereich:
$10.96
$12.57
52-Wochen-Spanne:
$10.83
$21.40
Crescent Biopharma Inc Stock (CBIO) Company Profile
Firmenname
Crescent Biopharma Inc
Sektor
Branche
Telefon
617-430-5595
Adresse
300 FIFTH AVENUE, WALTHAM, CA
Vergleichen Sie CBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
11.11 | 190.48M | 6.67M | -47.55M | -17.44M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.20 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-25 | Eingeleitet | Jefferies | Buy |
| 2025-08-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-14 | Eingeleitet | Wedbush | Outperform |
| 2025-06-25 | Eingeleitet | Stifel | Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-11 | Eingeleitet | Noble Capital Markets | Outperform |
| 2024-07-26 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-22 | Eingeleitet | CapitalOne | Overweight |
| 2021-11-12 | Hochstufung | Jefferies | Hold → Buy |
| 2021-04-29 | Fortgesetzt | Stephens | Overweight |
| 2021-02-10 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-21 | Eingeleitet | Raymond James | Outperform |
| 2019-11-14 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-05 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-01-04 | Eingeleitet | Oppenheimer | Outperform |
| 2018-12-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-02-12 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-12-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-06-06 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-07-26 | Eingeleitet | SunTrust | Buy |
| 2016-06-30 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-03-17 | Bestätigt | Stifel | Buy |
Alle ansehen
Crescent Biopharma Inc Aktie (CBIO) Neueste Nachrichten
Will Crescent Biopharma Inc. (GKO0) stock beat value stocksJuly 2025 Technicals & Safe Capital Growth Plans - newser.com
GlycoMimetics adjusts merger terms with Crescent Biopharma - MSN
Will Crescent Biopharma Inc. (GKO0) stock benefit from Fed rate cutsJuly 2025 Update & Safe Entry Zone Identification - newser.com
Short Interest in Crescent Biopharma, Inc. (NASDAQ:CBIO) Grows By 103.8% - MarketBeat
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives $25.60 Consensus Target Price from Analysts - Defense World
Will Crescent Biopharma Inc. (GKO0) stock top growth indexesIPO Watch & AI Driven Stock Reports - newser.com
Will Crescent Biopharma Inc. (GKO0) stock hit Wall Street targetsJuly 2025 Decliners & Community Trade Idea Sharing Platform - newser.com
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
GlycoMimetics Shares Are Soaring Tuesday: Here's Why - MSN
What analysts say about Crescent Biopharma Inc GKO0 stockVolatility Adjusted Trading & Superior Wealth Building - earlytimes.in
Crescent Biopharma (NASDAQ:CBIO) Stock Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat
With 36% stake, Crescent Biopharma, Inc. (NASDAQ:CBIO) seems to have captured institutional investors' interest - Yahoo Finance
Jefferies Initiates Crescent Biopharma(CBIO.US) With Buy Rating, Announces Target Price $26 - 富途牛牛
LifeSci Capital Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $22 - 富途牛牛
H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛
Crescent Biopharma (NASDAQ:CBIO) Stock Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
Analysts Set Crescent Biopharma, Inc. (NASDAQ:CBIO) Price Target at $25.60 - Defense World
Crescent Biopharma (NASDAQ:CBIO) Stock Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World
Crescent Biopharma to Present at September Investor Conferences - AInvest
Crescent Biopharma (NASDAQ:CBIO) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Given Buy Rating at HC Wainwright - Defense World
Cancer Drug Developer Crescent Biopharma to Present at Major September Healthcare Conferences - Stock Titan
Stifel reiterates Buy rating on Crescent Biopharma stock at $28 target - Investing.com
Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - AInvest
This Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Jefferies Initiates Coverage of Crescent Biopharma with Buy Rating and $26 Price Target - AInvest
Jefferies initiates coverage on Crescent Biopharma stock with Buy rating By Investing.com - Investing.com Nigeria
Jefferies initiates coverage on Crescent Biopharma stock with Buy rating - Investing.com
Finanzdaten der Crescent Biopharma Inc-Aktie (CBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):